VRK is a new kinase family of unknown function. Endogenous human vacinia-related kinase 2 (VRK2) protein is present in both the nucleus and the cytosol, which is a consequence of alternative splicing of two VRK2 messages coding for proteins of 508 and 397 amino acids, respectively. VRK2A has a C-terminal hydrophobic region that anchors the protein to membranes in the endoplasmic reticulum (ER) and mitochondria, and it colocalizes with calreticulin, calnexin and mitotracker; whereas VRK2B is detected in both the cytoplasm and the nucleus. VRK2A is expressed in all cell types, whereas VRK2B is expressed in cell lines in which VRK1 is cytoplasmic. Both VRK2 isoforms have an identical catalytic N-terminal domain and phosphorylate p53 in vitro uniquely in Thr18. Phosphorylation of the p53 protein in response to cellular stresses results in its stabilization by modulating its binding to other proteins. However, p53 phosphorylation also occurs in the absence of stress. Only overexpression of the nuclear VRK2B isoform induces p53 stabilization by post-translational modification, largely due to Thr18 phosphorylation. VRK2B may play a role in controlling the binding specificity of the N-terminal transactivation domain of p53. Indeed, the p53 phosphorylated by VRK2B shows a reduction in ubiquitination by Mdm2 and an increase in acetylation by p300. Endogenous p53 is also phosphorylated in Thr18 by VRK2B, promoting its stabilization and transcriptional activation in A549 cells. The relative phosphorylation of Thr18 by VRK2B is similar in magnitude to that induced by taxol, which might use a different signalling pathway. In this context, VRK2B kinase might functionally replace nuclear VRK1. Therefore, these kinases might be components of a new signalling pathway that is likely to play a role in normal cell proliferation. mammals, the VRK family has three members. The kinase domain of the VRK proteins shows relatively weak conservation [1] , but is catalytically active for VRK1 [11] [12] [13] [14] and VRK2, although not for VRK3 [13] . VRK1 has a nuclear localization signal and is detected in the nucleus in some cell lines and in transfected cells [11, 13] , but it is also present in the cytosol in other cell lines [15] , particularly in some types of adenocarcinoma (unpublished results); however, the regulation and coordination of the subcellular localization of different VRK proteins are unknown. The VRK1 protein is able to phosphorylate several transcription factors such as p53 [11, 15] , c-Jun16, and ATF2 [17] . VRK1 and VRK2 share 61% identity in their catalytic domains, with no conservation in other parts of the protein, suggesting functional differences between the two kinases that have yet to be characterized. It has been postulated that this protein family might play a role in proliferation because they are highly expressed in early haematopoietic development in murine embryos [18] , in tissues containing proliferative cells and in tumour cells [7] . VRK1 is expressed at very high levels in retinal neurons and its expression decreases dramatically the first day after birth [19] , it also correlates with proliferation markers in head and neck squamous carcinomas [20] . In chronic myelogenous leukaemia, expression of VRK1 can differentiate those who will respond to imatinib treatment from those who will not [21] . In B cells, analysis by quantitative MS indicates that it is downregulated when Myc expression is induced [22] . VRK1 is also regulated in response to peroxixome proliferators in murine hepatocytes [23] . VRK1 expression is activated in E2F and inhibited by p16 and in nonphosphorylated retinoblastomas [24] . The data available on VRK2 are much more limited. VRK2 is downregulated in human mononuclear B cells during the innate immune response to bacteria [25] , and upregulated in T cells by CD3 ligation and if costimulated by CD28 [26] .
VRK1 contributes to p53 stability via two mechanisms, one of which is dependent on Thr18 phosphorylation. It also appears to be implicated in the control of normal proliferation in the absence of cellular stress, and its inactivation by specific RNA interference blocks cell division [15] , consistent with observations in C. elegans, where it is embryonic lethal. In adult C. elegans there is a slowdown in growth suggesting problems in cell-cycle progression [2] . The p53 protein plays a major role in controlling the cell response to many types of cellular stress [27, 28] , and its intracellular levels appear to determine the susceptibility of a cell to tumour development [29, 30] . Regulation of p53 protein levels and transcriptional activity are therefore critical to allow for both normal cell division and tumour suppression, while retaining the capacity for rapid induction in response to genotoxic stress [31, 32] . Thus, its levels are tightly regulated, mainly by phosphorylation [33] .
Several kinases are implicated in the stability of p53 by targeting at least seven different residues in its N-terminal transactivation domain [34, 35] , each modulated by different types of stimulation [36] [37] [38] [39] [40] [41] . Therefore, there are functional differences regarding p53 stability or transcriptional activity depending on the residue phosphorylated [42, 43] . Phosphorylation of human p53 at Ser15 or Ser20 (equivalent to murine Ser18 and Ser23) promotes p300 recruitment and therefore its acetylation by p300 [43] [44] [45] , but p53 can also be stabilized in the absence of phosphorylation of these two residues [46] . Moreover, phosphorylation of murine Ser18 (human Ser15) is not necessary for p53 tumour suppression [47] . Cells also need to have a basic mechanism that maintains a basal level of p53 in a state of readiness and able to respond to any stress that may arise in normal life, when most cells are in interphase [15] . More recently, phosphorylation of p53 in Thr18 (Thr21 in murine p53) has acquired more relevance [48] , because it is implicated in both the p53-Mdm2 interaction and p300 recruitment. This residue is phosphorylated by casein kinase I delta only when it has previously been phosphorylated at Ser15 [49, 50] , but this kinase is cytosolic in interphase [51] ; Thr18 is uniquely phosphorylated by the nuclear VRK1 protein [11, 15] . Phosphorylation at Thr18 reduces binding to the p53-negative regulator Mdm2, and promotes its interaction with the cofactor p300. Mdm2 catalyses the ubiquitination of p53 and its subsequent proteolytic degradation [52] [53] [54] . p300 acetylates p53 at its C-terminus, promoting its transcriptional activation [55] [56] [57] [58] . The functional consequences of Thr18 phosphorylation are p53 stabilization and the activation of p53-dependent gene transcription [15] . Phosphorylation of Thr18 has been detected in cells treated with taxol and some other drugs [33, 59] , as well as in cellular senescence [60] , suggesting that several signalling pathways are involved.
We identified that VRK2 has different subcellular localizations corresponding to expression of two isoforms by the human VRK2 gene. Their expression varies depending on the cell type. Both isoforms have similar properties regarding their phosphorylation substrates and the specific phosphorylation of p53 in vitro. The nuclear VRK2B isoform might be functionally redundant with VRK1, and seems to be expressed in cells in which VRK1 is localized in the cytoplasm. In cells lacking nuclear VRK1 this nuclear isoform might regulate p53 mainly by phosphorylation.
Results

Localization of the endogenous human VRK2 protein
First we determined the subcellular localization of the endogenous VRK2 protein. For this, we used a specific rabbit polyclonal antibody against full-length VRK2 protein. We analysed the localization of VRK2 in two cell lines, WSI, derived from normal skin fibroblasts, and MCF7 cells from a breast carcinoma. In both cell lines there was strong staining in both the cytosol and nucleus, and there was a particulate aspect, suggesting that VRK2 might be associated with some organelle (Fig. 1A,B) . To further refine the subcellular distribution, three additional markers were included; the endoplasmic reticulum (ER) was identified by detecting calnexin (Fig. 1A ), mitochondria were detected with mitotracker ( Fig. 1B) , and nuclei were detected with DAPI staining (Fig. 1A,B) . Confocal microscopy analysis showed that a significant fraction of the endogenous protein was membrane bound both to the ER and, to a lesser extent, to mitochondria, as detected by the overlapping signals. The data suggested that endogenous VRK2 protein could exist in two forms, membrane bound, as detected in the ER and mitochondria, or free as detected in both cytosol and nuclei.
The VRK2 gene generates by alternative splicing two different isoforms that differ in their C-terminus
The detection of two subcellular locations for the known VRK2 protein suggested that these might be due to differences in the expression of the unique human VRK2 gene. To test this possibility, VRK2 cDNA from HeLa cells was cloned by RT-PCR. Two cDNA sequences of 1833 and 1877 nucleotides were isolated. Comparison of these sequences with the human VRK2 gene shows that they were generated by alternative splicing. Isoform B had an additional exon of 44 nucleotides, designated new exon 13 that changed the reading frame and included an early termination codon. Exon 13 is located 8280 base pairs downstream of exon 12 and 4542 base pairs upstream of exon 14, former exon 13, in the genomic sequence of the VRK2 gene ( Fig. 2A) . The resulting VRK2 proteins, A and B, have 508 and 397 amino acids, respectively. They differ in the C-terminus. In isoform A, this region (residues 395-508) contains a hydrophobic sequence (residues Fig. 1 . Subcellular localization of the endogenous human VRK2 protein in MCF7 and WSI cell lines. VRK2-specific detection was determined with a rabbit polyclonal antibody. DAPI staining, used to identify the nuclei, is also shown. The ER was identified with a monoclonal antibody specific for calnexin (A). Mitochondria were detected using the MitoTracker Red CMXRos reagent (B). Bars ¼ 50 lm.
487-506). In isoform B, this region is replaced by three amino acids (VEA), however, the catalytic domain at the N-terminus is identical (Fig. 2B ).
Differential expression of VRK2A and VRK2B proteins in tumour cell lines
To demonstrate that the two messages identified code for real proteins, we determined their presence in a panel of tumour cell lines using western blot analysis, with a polyclonal antibody raised against full-length VRK2 protein (isoform A), but that recognizes the N-terminal region common to both isoforms (not shown). The VRK2A protein was detected in all cell lines, but VRK2B protein was more abundant in some cell lines, such as C4-I, HeLa, MCF7 or the colon carcinoma WiDr, and detected in smaller amounts in the remaining carcinoma cell lines (Fig. 3A) . In lymphoma cell lines, only isoform A was detected. To identify the mobility of each protein, protein extract of MCF7 cells was run in parallel with the purified VRK2A and VRK2B proteins expressed as glutathione S-transferase (GST)-fusion proteins and digested with thrombin. We observed identical mobility in the endogenous proteins with the cloned and purified isoforms (Fig. 3B) .
The relative concentration of mRNA was also determined by real-time quantitative PCR in the H1299 and MCF7 cell lines. In this experiment, total and specific VRK2B messages were detected. In both cases there was always more VRK2A than VRK2B mRNA, and the two cell lines appeared to have similar levels of each message (Fig. 3C ). The nuclear localization of VRK2 suggests that it might be redundant, with VRK1 reported to be exclusively nuclear in transfection experiments [11, 13, 15] . However, the nuclear localization of VRK1 is dependent on the cell type, in lymphomas, sarcomas and squamous carcinomas it is nuclear, but in some adenocarcinomas it is cytosolic (manuscript in preparation). Therefore, the localization of endogenous VRK1 and VRK2 proteins was simultaneously determined by confocal microscopy in MCF7 cells from a breast adenocarcinoma, A549 cells from lung adenocarcinoma and HeLa cells from a cervical adenocarcinoma. Immunofluorescence showed that VRK1 is cytosolic with a particulate aspect in these three cell lines, whereas VRK2 is located in both the cytoplasm and is clearly detected in the nucleus (Fig. 3D) . In MCF7 and HeLa cells the strong staining in the nucleus coincides with the more abundant expression of VRK2B detected by western blot. The mobility of endogenous VRK2A and VRK2B proteins from MCF7 cell extracts was compared with bacterially expressed and purified GST-VRK2A and GST-VRK2B proteins that were digested with thrombin. The VRK2 isoforms were detected in the western blot with a rabbit VRK2-specific polyclonal antibody. (C) Quantitative detection by real time RT-PCR of total VRK2 (isoform A plus B) messages (solid lines) or specific VRK2B message (dotted lines) in the H1299 (blue) and MCF7 (pink) cell lines. (D) Localization of endogenous VRK1 and VRK2 proteins in three adenocarcinoma cell lines. VRK1 was detected with a mouse monoclonal antibody specific for human VRK1. Human VRK2 was detected with a rabbit polyclonal antibody. Bar ¼ 50 lm.
The two VRK2 isoforms have a different subcellular localization
To identify and confirm the subcellular localization of both VRK2 isoforms the cDNA of each isoform was cloned in pCEFL-HA vector that contains an HA epitope tag (because there is no monoclonal antibody specific for each isoform), resulting in clones pCEFL-HA-VRK2A and pCEFL-HA-VRK2B. The presence of a hydrophobic tail in VRK2A suggests that this isoform might be associated with membranes. Cos1 cells were transfected with each of the constructs and the location of the transfected protein was determined with an anti-HA serum. Isoform VRK2A was localized to the membrane of the ER and nuclear envelope, as shown by its colocalization with calreticulin ( Fig. 4A) .
Isoform VRK2B, lacking the transmembrane domain, presented a diffuse pattern throughout the cytoplasm and some was even detected in the nucleus and outside the nucleolus. Because of this nuclear presence we tested whether VRK2B shares a subcellular location with a known target of the related VRK1 protein, such as the p53 tumour-suppressor protein [11, 12] . For this, H1299 (p53 -⁄ -) cells were cotransfected with either of the VRK2 isoforms and pCB6 + p53. VRK2B, but not VRK2A, and p53 proteins were detected in the nucleus, with some overlap in their fluorescence, and outside the nucleolus (Fig. 4B ).
Substrate specificity of VRK2 isoforms and p53 phosphorylation
Despite the C-terminal domain differences, the catalytic domains are identical in both VRK2 isoforms. To determine if there was any difference in substrate specificity between the two isoforms, a panel of substrates commonly used to characterize Ser-Thr kinases related to casein kinase I were used [1, 11] . Both isoforms phosphorylated casein, histone 2B and myelin basic protein in a similar manner, but did not phosphorylate histone 3 (not shown). Furthermore, the two VRK2 isoforms had a strong autophosphorylation activity in vitro when tested as GST-VRK2 fusion proteins (Fig. 5A) .
To identify substrates of the VRK2 kinase that are of biological relevance we analysed the effect on the phosphorylation of p53 in its N-terminus, transactivation domain, because it is a known substrate of its related kinase VRK1 [11] . For this we used several GST-p53 (murine) fusion proteins containing individual or combined substitutions of Ser or Thr residues [61, 62] . There was a loss of radioactive signal whenever the Thr18Ala substitution was introduced by itself or in combination with Ser15Ile or Ser20Ala. VRK2A and VRK2B have an identical in vitro phosphorylation pattern (Fig. 5A) , and Thr18 appears to be the main residue phosphorylated, as detected by a loss of and p53. H1299 cells were transfected with plasmids pGST-VRK2B or kinase-dead pGST-VRK2B(K169E) and pCB6 + p53 or pCB6 + p53T18A in the combinations indicated in the figure and their correct expression was checked in the cell lysate prepared 48 h after transfection (upper). The lysate was mixed with glutathione-Sepharose beads for 4-12 h at 4°C with and the beads were pulled-down by centrifugation. The proteins brought down with the beads were analysed in an immunoblot with specific antibodies (lower). (E) Lack of Hdm2 phosphorylation by the VRK2B isoform. As substrates VRK2B kinase two different Hdm2 proteins were used; a full-length protein with a His tag and a GST fusion protein of the Hdm2 amino terminus (residues 1-188). In the left panel is shown the Coomassie Brilliant Blue staining and in the right-hand panel is shown the incorporation of radioactivity.
phosphate incorporation. Similar results were obtained using a construct spanning p53 residues 1-85, 1-64 or 11-63. Phosphorylated GST-p53 was used to determine the incorporation of radioactivity in a phosphoamino acid analysis. Incorporation was seen only in threonine residues, which is unique in the common region (Fig. 5B) . Next, the phosphorylation of human p53 was studied using either a full-length protein or partial constructs. Phosphorylation was detected only in constructs within the N-terminal p53 region, as expected (Fig. 5C ), and no incorporation was detected associated with constructs spanning residues 90-390.
In kinase reactions the interaction between the kinase and substrate is very short. However, it is sometimes possible to detect stable intermediate complexes between a kinase and its substrate if the reaction cannot be performed. Therefore, to address the possibility that VRK2B might form a complex with p53 an experiment using different proteins, either wild-type or mutated, was designed. H1299 cells were transfected with pGST-VRK2B mammalian expression constructs, both the wild-type and the inactive kinase (pGST-VRK2B-K169E), which express a catalytically inactive form of VRK2B because it lacks the lysine essential for kinase activity. As a substrate we used p53 or its nonphosphorylatable p53T18A variant. Expression of the different proteins was confirmed in whole-cell lysates (Fig. 5D, upper) , and these lysates were used for a pull-down of GST-VRK2B-associated proteins identified by immunoblot analysis. Formation of a stable complex was detected when an inactive kinase VRK2B(K169E) was used, independent of the p53 status, either wild-type or mutated p53T18A. No stable complex could be formed between an active VRK2B and a nonphosphorylatable p53. The inability of an inactive kinase to transfer the phosphate resulted in the formation and detection of a stable intermediate VRK2B(K169E)-p53 complex (Fig. 5D, lower) .
Because the N-terminus of p53 interacts with Mdm2, the potential phosphorylation of Hdm2 (human Mdm2) was studied using either full-length protein or its N-terminus (residues 1-188), which is the region of interaction with p53, but we did not detect any phosphorylation by VRK2A or VRK2B isoforms ( Fig. 5E ; VRK2A not shown).
VRK2B but not VRK2A induces the accumulation of p53
The p53-Mdm2 interaction promotes p53 ubiquitination and degradation via the proteasome pathway. Phosphorylation of p53 at its N-terminus frequently results in disruption of this interaction and consequently in its stabilization [63] . Therefore, we determined using western blot analysis whether the phosphorylation of p53 by VRK2B or VRK2A also resulted in its stabilization. H1299 (p53 -⁄ -) cells were transfected with pCB6 + p53 and increasing amounts of pCEFL-HA-VRK2A or pCEFL-HA-VRK2B. VRK2B, but not VRK2A, induced an accumulation of p53, which was higher as the amount of transfected VRK2B was increased (Fig. 6 ). To confirm that both ) lung carcinoma cells were transfected with 25 ng of pCB6 + p53, and varying amounts (0, 2, 3 and 4 lg) of plasmids expressing pCEF--HA-VRK2A, pCEF--HA-VRK2B or the kinase dead pCEF--HA-VRK2B(K169E). Detection of total p53 from in whole-cell lysate extracts was carried out with a mix of DO1 and Pab1801 antibodies. At the bottom is shown the quantification of p53 normalized with b-actin depending on the kinase isoform used in the assay as the mean of two independent experiments. Western blots were performed using the specific antibodies indicated in Experimental procedures. HA-tagged VRK2 isoforms expressed in culture were active, an in vitro kinase assay with the immunoprecipitated protein was performed (data not shown). Therefore, p53 in vivo is one target of VRK2B, probably because they colocalize in the same compartment. However, VRK2A, which is in the cytosol in a membrane-bound form, is not able to induce p53 accumulation. To confirm that this was dependent on the activity of VRK2B, we used a construct pCEFL-HA-VRK2B(K169E) that expresses a catalytically kinase dead form of VRK2B because it lacks the lysine essential for kinase activity. Indeed, this inactive mutant of VRK2B did not induce accumulation of p53 (Fig. 6 ).
The stabilization of p53 by VRK2B is a post-translational effect
To determine whether the effect induced by VRK2B on the p53 levels is a consequence of post-translational modification, an experiment was performed in the presence of the protein synthesis inhibitor cycloheximide. H1299 cells were transfected with pCB6 + p53 or a combination of pCB6 + p53 and pCEFL-HA-VRK2A or pCEFL-HA-VRK2B, 36 h later cycloheximide was added and the levels of p53 were determined by immunoblots at different time points. The amount of protein was normalized to the level of b-actin. In the absence of VRK2B, p53 was degraded almost immediately, as expected, whereas its levels were stable for more than 8 h in the presence of VRK2B (Fig. 7) . A similar experiment was performed with VRK2A; this isoform did not protect p53 from degradation.
VRK2B stabilizes endogenous p53 and activates its transcriptional activity
Next we determined whether VRK2B could also stabilize the endogenous p53 protein. For this assay the A549 cell line (p53
) was used. After transfection with VRK2B, cells were treated with cycloheximide, and the level of endogenous p53 protein was determined at different times. The stability of endogenous p53 (half-life) was less than 20 minutes in the absence of VRK2B, but in its presence, the stability of p53 was significantly increased (Fig. 8A) . A consequence of this stabilization by VRK2B is that p53 might be transcriptionally active. To determine whether the VRK2 proteins affected transcription, A549 cells were transfected with a p53 synthetic reporter, plasmid p53-Luc, which contains several p53-response elements. VRK2B, but not VRK2A, activated this promoter (Fig. 8B) . In order to verify whether VRK2B affected the transcription of a p53 target gene we used the pMdm2-Luc reporter containing the Mdm2 promoter. VRK2B also activated the transcription of Mdm2 (Fig. 8B) . Next, A549 cells were transfected with increasing amounts of pCEFL-HA-VRK2B, and the luciferase activity of the p53-Luc reporter was determined. As VRK2B increased, so did endogenous p53-dependent transcription (Fig. 8C) .
p53 phosphorylation by VRK2B differs from that induced by adriamycin or taxol
We showed that VRK2B phosphorylates p53 in vivo at Thr18. First it was confirmed that transfected p53 was phosphorylated at Thr18 by VRK2B in H1299 cells (p53 -⁄ -). When the cells were transfected with VRK2B, there was an increase in p53 phosphorylation as shown by western blot analysis (Fig. 9A, upper) . However, because only a fraction of the cells were transfected and the p53-Thr18 phospho-specific antibody is not very sensitive, the specific signal is difficult to detect in whole-cell extracts. To improve detection, p53 was concentrated by immunoprecipitation, and phosphorylation at Thr18 was determined using a phosphorspecific antibody. Inclusion of VRK2B increased the phosphorylation of transfected p53 in Thr18 by approximately fourfold, as shown in Fig. 9A (lower) . The next step was to determine the phosphorylation of endogenous p53 protein in A549 cells (p53 + ⁄ + ) in the presence of overexpressed VRK2B; as a positive control for phosphorylation, cells were treated with either adriamycin or taxol. All, overexpression of VRK2B or drugs induced Thr18 phosphorylation as detected using a phosphor-specific antibody (Fig. 9B) . Thr18 phosphorylation was dependent on the dose of VRK2B. In the same experiment the phosphorylation of Ser15 was also determined. However, the relative phosphorylation of Thr18 was higher in the presence of VRK2B than in the presence of adriamycin, and was similar to that induced by taxol (Fig. 9B, middle) . VRK2B induced relatively higher phosphorylation of Thr18 with respect to Ser15 phosphorylation, while in the presence of taxol or adriamycin, both residues were phosphorylated equally (Fig. 9B, lower) , suggesting that VRK2B did not require previous phosphorylation on Ser15. The higher absolute signal in drug-treated cells is due to the fact that all cells responded, whereas only a fraction were transfected with the VRK construct.
VRK2B reduces p53 ubiquitination and promotes its acetylation by p300
Phosphorylation of p53 at its N-terminal region modulates its affinity for different binding proteins. Therefore, a consequence of p53 phosphorylation at Thr18 might be to change its binding characteristics to Mdm2 [58, 64, 65] . Based on the phosphorylated residue by VRK2B, the expected effect would be a reduction in the p53-Mdm2 interaction [54] , and consequently a decrease in its ubiquitination. In H1299 cells, transfection of VRK2B clearly reduces the ubiquitination of p53 by exogenous Mdm2 (Fig. 10A) , indicating that the phosphorylation induced by VRK2B might alter Activation of endogenous p53-dependent transcriptional activity by VRK2B. A549 cells were cotransfected with or without VRK2 isoforms and a p53 synthetic reporter plasmid (p53-Luc, containing p53 response elements) or a specific gene promoter (Mdm2-Luc,containing Mdm2 promoter). pBASIC and pSV40-Control reporters were used, respectively, as negative and positive controls of the luciferase assay. Reporter luciferase activity was normalized for transfection levels with Renilla luciferasa (pRL-tk).
(C) Dependence of transcriptional activation on the dose of transfected VRK2B. A549 cells were transfected with increasing amounts of pCEF--HA-VRK2B and 0.5 lg of p53-Luc reporter construct, and 0.3 lg of pRL-tk Luc. Luciferase activity was determined 48 h after transfection and normalized with Renilla luciferase activity. Data from at least three independent experiments were analysed with Student's t-test. *P < 0.05; **P < 0.005.
Differential stabilization of p53 by VRK2 isoforms S. Blanco et al.
the interaction of p53 and Mdm2, therefore causing p53 accumulation. The coactivator p300 also interacts with the p53 transactivation domain and contributes to p53 stabilization and activation. To test the possibility that phosphorylated p53 might bind to this transcriptional coactivator, H1299 cells were transfected with different combinations of VRK2B (pCEFL-HA-VRK2B), p53 (pCB6 + p53) and p300 (pHA-p300) expression constructs. The effect on p53 protein levels and degree of acetylation was determined by immunoblot analysis, with an antibody specific for acetylation in Lys373 and Lys382 of whole-cell extracts. Indeed, it was observed that VRK2B facilitates p53 acetylation (Fig. 10B) . The p53 protein was also concentrated by immunoprecipitation to improve detection of its acetylation. In the absence of p300, the acetylation of p53 was enhanced slightly by VRK2B, and was particularly noticeable when cotransfected with pCMV-p300-HA (Fig. 10C) , indicating that p53 stabilized by VRK2B was acetylated de novo.
Discussion
Alternative splicing of the human VRK2 gene generates two isoforms with a common kinase domain and a different C-terminus, which determines their subcellular location. VRK2A localizes to the ER, whereas VRK2B variant, in contrast to those previously detected by RT-PCR [13] , is detected in both the cytoplasm and nucleus, outside the nucleolus, despite lacking a known NLS. VRK2A is highly expressed in different cell lines, whereas VRK2B expression is more restricted and appears to be coordinated by an unknown mechanism. Because different cell types present different proportions of both isoforms, and the substrate specificities of both VRK2 isoforms and their relative VRK1 [11, 16, 17] are similar in vitro, we postulate that the biological effects mediated by these kinases might be determined by their subcellular localization and the proteins present in the corresponding compartment, and by their C-terminal domain, which mediates interactions with different proteins. Their regulation is likely to be controlled by the different C-terminus, which determines their interaction with other regulatory proteins not yet identified, but whose future identification will contribute to the unravelling of the signalling pathway to which these kinases belong. For instance, VRK2B and VRK1 are localized in the nucleus but differ in their last 90 amino acids in the C-terminus.
Stabilization of p53 is part of the response to cellular stress, and is usually mediated by phosphorylations carried out by a large number of kinases that target several different residues, mainly located in the p53 N-terminus, and generates a complex pattern of phosphorylation [33] . Furthermore, the p53 N-terminus mediates the interaction using many regulatory molecules such as acetyl transferases [58] and ubiquitin ligases, for example, its downregulator Mdm2 [66] . The specificity of the interactions can be modulated by phosphorylation at different residues, of which Ser15 and Ser20 are the best characterized, and result in p53 stabilization [41] . However, stabilization can also occur in the absence of Ser15 or Ser20 phosphorylation [46] , in this case, Thr18 phosphorylation is the other likely mechanism for p53 stabilization. Thr18 phosphorylation is mediated by some kinases, of these casein kinase 1 delta requires the previous phosphorylation of Ser15 [50] and is cytosolic in interphase [51] , whereas VRK1 or VRK2B phosphorylate Thr18 directly and are nuclear proteins [11] . Thr18 phosphorylation contributes to p53 stabilization. The other VRK2A, which has a different subcellular location and does not colocalize with p53, is not able to induce stabilization. Cytosolic VRK2A is therefore more like casein kinase 1 delta as both phosphorylate Thr18 in vitro [50] . Therefore, a different subcellular location and different modulation of a common kinase domain may determine different biological activities. Phosphorylation of , a deacetylase inhibitor. Cells were lysed in the acetylation-precipitation buffer with TSA, and p53 was immunoprecipitated with a mix of DO1 and Pab240 antibodies. The acetylation of p53 in residues Lys373 and Lys382 was determined with a specific antibody as indicated in Experimental procedures. The constructs used in transfections were pCB6 + p53, p-CEFL-HA-VRK2B and pCMV-p300-HA. The bar graph represents the mean of two independent experiments with its SD and *P < 0.05. (D) H1299 cells were transfected with plasmid encoding wild-type p53 or different substitution as indicated, with or without pCEF--HA-VRK2B. Detection of total p53 from in whole-cell lysate extracts was carried out with a mix of DO1 and Pab1801 antibodies.
Thr18 has been observed in vivo in cells treated with taxol [59, 67] and in senescent fibroblast [60] . However, the phosphorylation at Thr18 induced by taxol or adriamycin is also accompanied by the phosphorylation of Ser15, probably via activation of stressresponse pathways; this is not the case for VRK2B, which is probably mediated via a different signalling pathway or cooperates with some of these stressresponse pathways. It has also been postulated that Thr18 phosphorylation might play a role in normal growth [15] , and this may be the reason for its detection in cellular senescence [60] . Phosphorylation of the N-terminus might be a regulatory mechanism for a docking site in p53, particularly in Thr18, which affects the interaction with either Mdm2 [54] or p300 [58, 64, 68] . The consequence of p53T18 phosphorylation is a disruption of p53 interaction with Mdm2, because this residue is essential for maintaining the structure of the p53-binding region [53, 54, 69] , by reducing p53 ubiquitination it contributes to its stabilization and promotes other protein interactions [15] . The coactivator p300 binds to p53 in the same region as Mdm2, and promotes its stabilization and transactivation by acetylation [70] . In the case of Thr18 phosphorylation by VRK2B, there is an increase in p53 stability and transactivation, as expected, if improved binding to p300 and disruption of the Mdm2 interaction were promoted by this phosphorylation [55, 58] . The effects observed regarding phosphorylation of human p53 in Thr18 are consistent with similar findings reported for the role of the equivalent residue in murine p53, Thr21 [48] , and it has also been reported that Thr18 phosphorylation by VRK1 stabilizes p53 and promotes its binding to Mdm4 and p300 [15] . Although p53 can be phosphorylated at several residues by many kinases, the precise functional consequences resulting from different combinations of phosphorylated residues are not well known.
It has been proposed that the nuclear kinase VRK1 has a role in the regulation of p53 in the cellular response to suboptimal stress during interphase [15] , which is the normal physiological situation. Phosphorylation of Thr18 is likely to be a component of a p53 cycle that is necessary to maintain basal levels of p53, these levels are needed if normal proliferation is to be able to respond to severe stress signals [15] . However, in adenocarcinoma tumour cell lines, VRK1 is localized in the cytoplasm, therefore it may not regulate p53. In this situation, the VRK2B isoform is expressed and is located in the nucleus where it might functionally replace VRK1 in this suboptimal protective role, given the similarity of their effect on p53. This indicates two novel levels of regulation of VRK proteins, one is the coordination of their expression, VRK2B is formed when VRK1 is cytosolic, but not when is nuclear; and the other is how VRK2B is transported to the nucleus because it lacks a nuclear localization signal, that is present in the C-terminus of VRK1 [11] . The effect of VRK2B on p53 Thr18 phosphorylation is functionally redundant with the effect of VRK1 [15] regarding p53. VRK2B can therefore functionally replace VRK1 in those cells where the latter is cytosolic, although they are likely to be regulated differently, because they differ in their C-terminus. This function would suggest that there should be some redundancy in these genes, and this would explain why the murine knockout of VRK2 is viable [71, 72] . The VRK family of Ser-Thr kinases represents the beginning of novel signalling pathways that operate in many cell types and that are beginning to be unravelled.
Experimental procedures
RNA extraction, RT-PCR, cloning and mutagenesis
Total RNA from H1299, HeLa and MCF7 was isolated using RNAeasy Mini Kit (Qiagen, Hilden, Germany). RNA was analysed and quantified using a Bioanalyser 2100 nano-lab chip from Agilent Technologies (Waldbronn, Germany). cDNA was synthesized as previously reported [11] . Different primers were designed to generate full-length VRK2 (nucleotides 130-1657; GenBank accession number AB000450) based on human VRK2 [7] . VRK2A: 5¢-CCCGGATCCATGCCACCAAAAAGAAATGAAAAAT ACAAACTTCC-3¢ (nucleotides 130-165), this primer has the initiation codon and a BamH1 cloning site. VRK2X: 5¢-GGGTCTAGAGGAATTTTGGTATCATCTTCAGAG-3¢ (nucleotides 1652-1675 antisense strand), with an XbaI cloning site and the termination codon. VRK2S: 5¢-GGGGTC GACGGAATTTTGGTATCATCTTCAGAG-3¢ (nucleotides 1652-1675 antisense strand), with a SalI cloning site and the termination codon. Human full-length VRK2 was made with primers VRK2A and VRK2X or VRK2S from HeLa RNA for cloning in pGEX4T-1 (Amersham Biosciences, Little Chalfont, UK). For expression in eukaryotic cells, the VRK2A and VRK2B full-length cDNA were subcloned in vector pCEFL-HA or pCEFL-GST with restriction sites BamHI-NotI, using primers VRK2A, VRK2Not1.A: 5¢-GGGCGGCCGCGGAATTTTGGTATC ATCTTCAGAG-3¢ and VRK2TN.1: 5¢-GCGGCCGCCTA AGCTTCTACCTGAGCTGCTTC-3¢. To detect the new exon in VRK2 transcripts two pairs of flanking primers were designed. Forward primer VRK2TA: 5¢-AGTGAGG AAGCGCTGAGTCCT-3¢, and reverse primer: VRK2TB: 5¢-CAAGAGTCTCAAGAACCTTTG-3¢ which amplify fragments of nucleotides 135-179 specific for isoform A and B messages, respectively, and forward primer VRK2TC: 5¢-GCAGCTCAGGTAGAAGCTTAGG-3¢, and reverse primer: VRK2TD: 5¢-CGTGCTGACTGTGGAAG TGT-3¢ specific for isoform B. One hundred nanograms of total RNA was used in a one-step RT real-time PCR amplification reaction using the 'Quantitec SYBR Green RT-PCR kit' from Quiagen in an iCycler (Bio-Rad, Hercules, CA). The reaction was analysed using icycler software (Bio-Rad). The VRK2B cDNA sequence has GenBank accession number AJ512204. An inactive or kinase-dead (KD) VRK2 mutation was made by site-specific mutagenesis introducing the K169E substitution in mammalian expression constructs and in GST fusion proteins. Sitedirected mutagenesis was performed with the Quick-Change Mutagenesis kit from Stratagene (San Diego, CA).
Plasmids and fusion proteins
The GST-p53 constructs containing the N-terminus of murine p53 and its mutants were a gift of D. Meek (Dundee University, UK) [61, 62] . The human GST-p53 fusion proteins, 1-390 (full-length), 90-290 and 290-390 were from T. Kouzaridis (Cancer Research UK, Cambridge, UK). Fulllength human pHdm2-his and N-terminus of pGST-Hdm2 (residues 1-188) were from A. Levine (Rockfeller University, New York). GST-fusion proteins were expressed in BL21DE3 cells and purified using glutathione-Sepharose (Amersham) as previously reported [11] . His-tagged proteins were expressed in, purified with TALON Metal Affinity Resin (BD Biosciences, Erembodegem, Belgium) and eluted with 100 nm imidazol (Merck, Darmstadt, Germany). Mammalian expression plasmids containing human p53 wild-type cDNA, pCB6 + p53, and pCOC-Mdm2-X2 were from K. Vousden (Beatson Institute, UK) and plasmid pCMVb-p300-HA was from R. Eckner (University of Zurich). The ubiquitin tagged with a His epitope for mammalian expression (clone BRR12-His-ubiquitin) was from S. Lain and D. Lane (Dundee University, UK). Plasmid pMdm2-Luc was a gift from B. Vogelstein. The p53-cis reporter plasmid (p53-Luc) with the luciferase gene was from Stratagene (La Jolla, CA). [11] . The phosphorylated products were analysed in an SDS-polyacrylamide gel and the incorporation of radioactivity was determined either by autoradiography or in a Molecular Imager FX (Bio-Rad). Phosphoamino acid analysis was performed as previously described [16, 17] .
Ser-Thr kinase activity assay
Acid hydrolysis and phosphoamino acid analysis
An in vitro kinase assay was performed with GST-VRK2B and GST-p53 (FP267) as substrates. The phosphorylated proteins were fractionated by SDS ⁄ PAGE and transferred onto an Immobilon-P filter (Millipore, Bedford, MA), radioactive bands corresponding to GST-p53 were excised and the protein was eluted. The eluted protein was hydrolysed with 200 lL of 6 n HCl at 110°C for 1 h. The sample was freeze-dried and resuspended in a mixture containing 2 lL of a stock solution at 1 mgAEmL )1 of P-Ser, P-Thr and P-Tyr as reference markers, 1 lL of 1% bromophenol blue and 2 lL of formic acid ⁄ acetic acid ⁄ water (1:3.1:35 v ⁄ v ⁄ v) pH 1.9. The mixture was applied to a cellulose chromatoplaque (Merck) and subjected to flat-bed electrophoresis in a Multiphor II system (Amersham Biosciences) at 1.5 kV for 90 min. After air drying, the radioactivity on the chromatoplaque was exposed to X-ray film. Phosphoamino acid markers were detected by staining with a 0.25% ninhydrin solution in acetone.
Cell lines, transfections and luciferase reporter assay 0.5 · 106 A549 cells were seeded in 60 mm dishes and 24 h later were transfected in triplicate with JetPEI reagent and 0.5 lg of p53-Luc as luciferase reporter, and increasing amounts of pCEF--HA-VRK2A or pCEF--HA-VRK2B and as internal control for transfection we used 0.3 lg of pRenilla-tk (pRL-tk) reporter plasmid from Promega (Madison, WI). Cells were lysed 48 h after transfection and luciferase activity was determined with Dual-luciferase Reporter Assay System (Promega) in a luminometer Minilumat LB9506 (Berthold, Bad Wildbad, Germany).
Immunofluorescence
Cells were seeded in 60 mm dishes, grown on a coverslip and transfected as indicated in specific experiments with pCEF--HA-VRK2A and -B and also pCB6 + p53 in the H1299 cell line using the calcium phosphate precipitation method; 48 h post transfection the slides were collected and fixed with 3% paraformaldehyde for 30 min at room temperature, treated with 10 mm glycine for 10 min at room temperature and then permeabilized with 0.2% Triton X-100 for 30 min at room temperature. The cells were blocked with 1% bovine serum albumin (BSA) in NaCl ⁄ P i for 30 min at room temperature followed by double immunostaining with the corresponding antibodies. Finally, cells were stained with DAPI (Sigma) 1:1000 in NaCl ⁄ P i for 10 min at room temperature, washed with NaCl ⁄ P i , and slides were mounted with Gelvatol (Monsanto). The analysis was performed with a Zeiss LSM510 confocal microscope.
Western blot analysis, immunoprecipitation, pull-down assays and antibodies Cells were harvested 48 h post transfection and lysed with RIPA buffer (150 mm NaCl, 1,5 mm Mg Cl 2 , 10 mm NaF, 100% glycerol, 4 mm EDTA, 1% Triton X-100, 0,1% SDS, 50 mm Hepes pH 7,4, protease and phosphatase inhibitors) or in acetylation immunoprecipitation buffer (50 mm Hepes, pH 7.8, 200 mm NaCl, 1% Triton X-100, 10 mm EDTA, 5 mm dithiothreitol, 5 lm trichostatin A and protease and phosphatase inhibitors). Fifty micrograms of total protein lysate were analysed in a 10% SDS-polyacrylamide gel. Cell lysates were subjected to p53 immunoprecipitation with monoclonal antibodies DO1 and pab240 (Santa Cruz Biotchnology, Santa Cruz, CA) at 4°C overnight, followed by adsorption to c-Bind (Amersham Biosciences) and analysed in a 7.5% SDS-polyacrylamide gel. For GST pulldown assays cells were lysed with a buffer containing buffer 20 mm Tris ⁄ HCl pH 7.4, 137 mm NaCl, 2 mm EDTA, 25 mm b-glycerophosphate, 2 mm pyrophosphate, 10% (v ⁄ v) glycerol and 1% Triton X-100 plus protease inhibitors. GST pull-downs were performed by incubating 1 mg of total cell extract with glutathione-Sepharose 4B beads (Amersham Pharmacia Biotech) for 12 h at 4°C. Sepharose beads were washed three times with lysis buffer and analysed by SDS ⁄ PAGE. To detect endogenous VRK2 a rabbit polyclonal antibody which recognized both isoforms was prepared by immunizing rabbit with human VRK2A GST-fusion protein. VRK1 was detected with a mouse monoclonal antibody, clone 1F6, prepared against the human VRK1 protein. The monoclonal antibody specific for the HA epitope was from Covance (San Francisco, CA). The polyclonal antibody specific for calreticulin was from Calbiochem (La Jolla, CA) and monoclonal anti-(calnexin AF18) was from Santa Cruz. p53 protein was detected with a mix of DO1 antibody (Santa Cruz) and Pab1801 (Santa Cruz) used at 1:500 and 1:1000, respectively. To detect the phosphorylation of p53 in Thr18 and in Ser15 rabbit polyclonal antibody, P-p53 (Thr18)-R, and a monoclonal P-p53 (Ser15)-R from Santa Cruz were used. A rabbit antiserum from Upstate Biotechnology (Lake Placid, NY) detecting specifically acetylated p53 in Lys373 and 382 was used. SMP14 monoclonal antibody (Santa Cruz) was used to detect the Mdm2 protein. The monoclonal anti-(bactin) was from Sigma. Mitochondria were detected using the MitoTracker Red CMXRos reagent (Molecular Probes, Eugene, OR). The secondary antibodies used from Amersham were an anti-(mouse-Cy2) (Fluorolink Cy2), anti-(rabbit-Cy3) (Fluorolink Cy3) and anti-(rabbit-Cy2) (Fluorolink Cy2) for immunofluorescence, or an anti-(mouse-HRP) or anti-(rabbit-HRP) for western blots. Luminescence in western blot was developed with an ECL kit (Amersham Biosciences).
